Thanks to tiny microneedles, eye doctors may soon have a better way to treat diseases such as macular degeneration that affect tissues in the back of the eye. That could be important as the population ages and develops more eye-related illnesses – and as pharmaceutical companies develop new drugs that otherwise could only be administered by injecting into the eye with a hypodermic needle, according to a Georgia Institute of Technology press release.
For the first time, researchers from the Georgia Institute of
Technology and Emory University have demonstrated that microneedles less
than a millimeter in length can deliver drug molecules and particles to
the eye in an animal model. The injection targeted the suprachoroidal
space of the eye, which provides a natural passageway for drug injected
across the white part (sclera) of the eye to flow along the eye’s inner
surface and subsequently into the back of the eye. The
minimally-invasive technique could represent a significant improvement
over conventional methods that inject drugs into the center of the eye –
or use eyedrops, which have limited effectiveness in treating many
diseases. Read more.